Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeuGcGM3 + VSSP + Montanide ISA 51
- Development stage
- Preclinical
- Lead developer
- Center for Molecular Immunology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
NeuGcGM3 + VSSP + Montanide ISA 51 is a combination therapeutic cancer vaccine. It combines the NeuGcGM3 antigen with VSSP (Very Small Size Proteoliposomes) as an immunostimulant and Montanide ISA 51 as an adjuvant. Montanide ISA 51 is a vaccine adjuvant that creates a depot effect at the injection site, allowing slow and prolonged release of antigens. This formulation enhances CD4+ and CD8+ T cell responses and amplifies antibody production specific to cancer antigens. The combination is designed to stimulate the immune system against cancer cells expressing the NeuGcGM3 ganglioside.
02
Targets
NeuGcGM3 (N-glycolyl-GM3 ganglioside)
Beyond the preview
Go deeper on NeuGcGM3 + VSSP + Montanide ISA 51.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuGcGM3 + VSSP + Montanide ISA 51.